Compile Data Set for Download or QSAR
maximum 50k data
Found 885 with Last Name = 'brun' and Initial = 'p'
TargetRelaxin receptor 1(Homo sapiens (Human))
Sanofi R&D

Curated by ChEMBL
LigandPNGBDBM50563230(CHEMBL4754949)
Affinity DataKi:  1.10nMAssay Description:Displacement of Eu3+-labelled H2 relaxin from human RXFP1 expressed in human HEK-293T cells in presence of 10 % FCS by competition binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetRelaxin receptor 1(Homo sapiens (Human))
Sanofi R&D

Curated by ChEMBL
LigandPNGBDBM50563231(CHEMBL4780098)
Affinity DataKi:  2.88E+3nMAssay Description:Displacement of Eu3+-labelled H2 relaxin from human RXFP1 expressed in human HEK-293T cells in presence of 10 % FCS by competition binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSodium channel protein type 8 subunit alpha(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50240277(CHEMBL4061793)
Affinity DataIC50:  0.0600nMAssay Description:Inhibition of human Nav1.6 alpha expressed in HEK293 cells incubated for 5 mins with 6 consecutive train pulses to -10 mV at 0.1 Hz and holding poten...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium channel protein type 8 subunit alpha(Homo sapiens (Human))
Merck

Curated by ChEMBL
LigandPNGBDBM50240278(CHEMBL4062780)
Affinity DataIC50:  0.0900nMAssay Description:Inhibition of human Nav1.6 alpha expressed in HEK293 cells incubated for 5 mins with 6 consecutive train pulses to -10 mV at 0.1 Hz and holding poten...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPolyunsaturated fatty acid 5-lipoxygenase(Mus musculus)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50043670(2-{(S)-1-[3-Fluoro-5-(naphthalen-2-ylmethoxy)-phen...)
Affinity DataIC50:  0.700nMAssay Description:Inhibition of 5-lipoxygenase from mouse macrophageMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645460(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645461(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645462(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645463(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645464(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645465(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645466(1-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645467(1-(4-((6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645468(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645469(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645470(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645471(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645472(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645473(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645474(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645475(N-(4-{[6-(5-chloro-2,4- difluorophenyl)-3- methylp...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645476(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645477(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645478(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645479(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645480(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645481(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645482(US20240018122, Example 162 | cis N-(4-{[6-(5-chlor...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645483(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645484(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645485(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645486(N-4-[6-(5-chloro-2- fluorophenyl)-3- methylpyridaz...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645487(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645488(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- methylpyrid...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645489(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- cyclopropyl...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645490(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- (hydroxymet...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645491(US20240018122, Example 175 | methyl N-[2-(4-{[(4-{...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645492(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- (hydroxymet...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645493(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- (hydroxymet...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645494(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- (hydroxymet...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645495(US20240018122, Example 180)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645496(US20240018122, Example 181)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645497(N-(4-((6-(5-chloro-2- fluorophenyl)-3- (trifluorom...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645498(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- (trifluorom...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645499(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- (trifluorom...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645500(N-(4-{[6-(5-chloro-2- fluorophenyl)-3- (trifluorom...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645501(US20240018122, Example 187 | methyl 3-[6-(5-chloro...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645502(US20240018122, Example 189 | methyl (1r,4r)-4-(6-(...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645503(N-[4-({6-[5-(difluoromethyl)- 2-fluorophenyl]-3- m...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645504(US20240018122, Example 191 | methyl 4-(6-(5-chloro...)
Affinity DataIC50: <1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 885 total ) | Next | Last >>
Jump to: